Satellos Bioscience Inc. — Form F-10
Filed August 11, 2026 · analyzed by the Registration Agent
F-10
— Neutral
significance 28/100
What the filing says
Satellos Bioscience Inc., a Canadian clinical-stage biopharmaceutical company, filed an amended and restated short-form base shelf prospectus on August 11, 2026, registering up to US$300 million in aggregate securities (common shares, preferred shares, warrants, units, subscription receipts, and debt securities) for issuance over 25 months. The company is developing SAT-3247, an orally administered AAK1 inhibitor for Duchenne muscular dystrophy, currently in two clinical trials (BASECAMP and TRAILHEAD). Recent developments include FDA Fast Track designation for SAT-3247 (June 29, 2026) and six-month interim data from TRAILHEAD (July 8, 2026) showing reduced muscle fat fraction and stable strength in four adult patients.
Why this rating
Shelf prospectus is routine capital-raising mechanism for biotech companies; no specific issuance amount disclosed yet. Company has ~US$70M cash (March 2026), sufficient through 2027 per management.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.